申请人:Hu Baihua
公开号:US20100120778A1
公开(公告)日:2010-05-13
Disclosed are quinoxaline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I):
wherein:
each of L
1
and L
2
is, independently, a bond, —O— or —NH—;
R
2
is C
6
-C
10
aryl or heteroaryl including 5-10 atoms, each of which is (i) substituted with 1 R
9
, and (ii) optionally further substituted with from 1-4 R
e
; and
each of R
4
and R
5
is, independently (i) hydrogen; or (ii) halo; or (iii) C
1
-C
6
alkyl or C
1
-C
6
haloalkyl, each of which is optionally substituted with from 1-3 R
a
;
and R
1
, R
3
, R
6
, R
9
, R
a
and R
e
are defined herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.
公开了基于喹诺克的Liver X受体(LXRs)调节剂及相关方法。这些调节剂包括以下式(I)的化合物:
其中:
L1和L2分别独立为键,-O-或-NH-;
R2是C6-C10的芳基或杂芳基,包括5-10个原子,每个原子(i)带有1个R9基团,和(ii)可选地带有1-4个Re基团;
R4和R5分别独立为(i)氢;(ii)卤素;或(iii)C1-C6的烷基或C1-C6的卤代烷基,每个都可选地带有1-3个Ra基团;
以及R1、R3、R6、R9、Ra和Re都在此定义。
一般来说,这些化合物可用于治疗或预防一个或多个由LXRs介导的疾病、失调、状况或症状。